There’s a question that has bugged me for a long time. Why does software eat the world in a decade, while healthcare, the field that literally keeps us alive, so often feels stuck?
The contrast is hard to ignore. In a few decades, information technology rewired daily life. AI went from science fiction to something sitting in your pocket. Computers write software, translate languages, recognize faces, drive cars, and help chemists stumble onto new materials. The internet connected billions of people. One person with a laptop can build a product used by millions. Whole industries get replaced on a rolling basis: something launches, flops, mutates, and gets outdone by something better, sometimes within a single quarter.
Meanwhile, a long list of health problems feels almost identical to what it was a generation ago. Hair loss. Cancer. High blood pressure. Obesity. Excessive sweating. Chronic pain. Autoimmune disease. Neurodegeneration. Conditions that touch millions of lives and still don’t have anything you’d call a clean answer.
I want to be fair here, because medicine has done extraordinary things. Vaccines, antibiotics, modern surgery, imaging, transplants, and emergency care. These have saved a staggering number of lives, and none of it is small. But the question still sits there: why do some problems that have been around for decades or centuries still have no definitive fix? And a slightly more uncomfortable version of the same question: is the slowness only about scientific difficulty, or is the structure of the industry itself part of the drag?
Software and medicine play by different rules #
Picture a developer with a new idea for building a web app. They can prototype it, test it, ship it, and watch users react. Users might hate it. The product might die. The developer might realize the whole premise was wrong. What they generally don’t do is lose their license to work because their architecture was unconventional.
That’s the culture IT built. Experimentation is normal. A programmer can say, “I think there’s a better way to do this,” try it, and either learn from the failure or ship something that matters.
Healthcare doesn’t work that way, and for good reason. A doctor who wants to try an unconventional treatment can’t just run the experiment on patients the way a developer runs it on code. Lives are on the line, so the caution is understandable. But there might be a hidden cost. When a system gets so good at protecting patients from dangerous experiments that it also makes ordinary experimentation nearly impossible, something is lost. What happens when an institution becomes so afraid of mistakes that it becomes afraid of breakthroughs, too?
When certification quietly turns into a ceiling #
Medical certification exists for obvious reasons. Patients need protection from people who don’t know what they’re doing. Treatments should be tested, evidence should matter, and nobody should get to freelance on human beings.
But certification can produce a side effect nobody intended. Over years of training, a professional can be shaped to operate the accepted system rather than to question it. The point isn’t “let doctors do whatever they want.” Of course not. The sharper question is whether there should be a protected space where qualified people can chase unconventional ideas without automatically putting their entire career at risk.
Right now, a doctor who says something that cuts against established thinking can face real professional pressure. If they turn out to be wrong, they get criticized, which is fair enough. But what about the times they turn out to be right? A lot of scientific progress started with exactly this move, someone doubting the consensus. The trouble in medicine is that the price of being unconventional may be steeper than in almost any other field.
Where’s the medical version of a startup incubator? #
Tech has incubators, accelerators, open-source communities, hackathons, beta channels, and a whole ecosystem built around trying things. A developer can build in a garage. A small team can take a real swing at a company worth billions.
Healthcare has research labs, obviously. But the road from a strange idea to something that reaches a patient tends to be long, expensive, and brutal. So maybe healthcare needs a genuinely new category.
Imagine a legally recognized space where licensed doctors, scientists, engineers, and researchers could investigate unconventional approaches under strict but flexible rules. Not a free-for-all. Not a place where patients become test subjects without protection. Something closer to a controlled middle ground between everyday clinical practice and pure lab research.
In a space like that, people could test hypotheses that don’t fit neatly into current frameworks, collaborate across disciplines, throw AI at large datasets, combine existing technologies in ways nobody has bothered to try, and publish the failures alongside the wins. The organizing principle would be protection for responsible innovation. A doctor shouldn’t lose their license for exploring a serious idea that hasn’t gone mainstream yet. There’s a real difference between someone who recklessly endangers patients and a careful professional investigating something new, and the system should be able to tell them apart.
Are pharmaceutical companies part of this? #
This one’s uncomfortable, but it’s worth asking honestly. Pharmaceutical companies are businesses. Their job is to make products that generate revenue, and that alone doesn’t make them villains. Developing a drug is enormously expensive, and these companies have produced treatments that changed millions of lives.
Still, the business model creates a gravitational pull. A company is naturally more inclined to fund something that promises a large, predictable, recurring revenue stream. Which raises an awkward comparison. Is the industry more drawn to curing a disease once, or to managing it for twenty years? A permanent cure is usually better for the patient. A daily treatment taken for two decades is often better for the balance sheet.
I don’t think this means companies are sitting on cures in a vault somewhere. The reality is subtler and, in a way, more concerning. Money, talent, and attention drift toward whatever is commercially attractive, and some potentially transformative ideas simply never get funded well enough to be tested properly. So the useful question isn’t “are pharma companies secretly blocking every cure,” which is a cartoon. It’s whether the economics of the field quietly favor incremental improvement over radical breakthroughs. My honest guess is that they often do.
Are doctors punished for being wrong in the wrong way? #
A doctor sits in a genuinely tough spot. Follow the accepted standard of care and get a bad outcome, and you can at least say you did what the field agreed was correct. Try something unconventional, even something grounded in real research, and a bad outcome can bring legal, professional, and reputational consequences down on your head.
That asymmetry creates a powerful pull toward staying inside the lines. The safest career move is usually to do what everyone else does. And this is human, not cowardly. Doctors have families, mortgages, and reputations. Why would anyone gamble all of that to chase a controversial idea when the system can punish them even when their intentions were good?
What you get, over time, is a kind of intellectual conservatism. Not because doctors lack intelligence or don’t care, but because the incentives reward compliance and penalize deviation.
Take hair loss as a small example #
Hair loss is a useful case precisely because it seems minor. It affects an enormous number of people, it can cause real psychological distress, and the biology of hair growth has been studied for decades. Yet the options are still thin. Some treatments help some people. Some have side effects, some need to be used forever, some are expensive, some are surgical, and plenty of people never find anything that works for them.
Is the problem genuinely hard? Almost certainly. But it’s worth asking whether we’re circling it from the wrong angle. Maybe the answer isn’t yet another variation on the same pharmaceutical theme. Maybe it lives at the intersection of regenerative medicine, cell biology, genetics, tissue engineering, and immune research, in territory that doesn’t fit tidily into any existing category. And if so, whose job is it to go looking there? How many unconventional ideas never get a serious look simply because they don’t map onto the way research is currently organized?
Why cancer is still so hard #
Cancer isn’t one disease. It’s a sprawling family of them, which is a big part of why it’s so difficult. But it also exposes a second problem in how we innovate.
We’re not short on tools. We have mountains of data, powerful computers, capable AI, cheap genome sequencing, and the ability to simulate complicated biological systems. And cancer is still one of the hardest problems in medicine. The next breakthrough might come from traditional drug development. It might also come from somewhere else entirely: AI, personalized cell therapies, nanotechnology, or some combination of existing treatments that nobody tested because no single organization had both the incentive and the authority to try. The question worth sitting with is whether the current system makes it easy enough for genuinely different ideas to get a fair test.
Obesity and blood pressure keep winning #
Obesity and high blood pressure are among the most common health problems on the planet. We understand many of the contributing factors. We have medications, surgeries, dietary advice, and shelves of research. And the problems are still everywhere.
Maybe these are tangled social and biological problems rather than single diseases with a single cure. Fine. But that shouldn’t be where the conversation stops. It should be where it starts. We have a strange habit of accepting a problem as permanent just because it’s difficult. If IT had that reflex, we might still be on dial-up. Tell a software engineer in 1995 that the internet is slow and unreliable, and that’s just how technology is, and they’d have looked at you like you’d lost your mind. So why do we let some health problems go on for decades?
What a moonshot culture might look like here? #
Tech has gotten genuinely good at ambitious, borderline absurd goals. Land people on the Moon. Land rockets back on their tails. Build AI. Connect billions of people. Chase quantum computers. Healthcare could use more of that spirit, and I don’t mean recklessness or throwing out evidence. I mean a willingness to say: this problem has been around forever, so maybe we need to think about it in a completely different way.
Picture a dedicated moonshot program for each major unsolved condition. A global, cross-disciplinary effort pulling in doctors, biologists, engineers, computer scientists, AI researchers, drug developers, entrepreneurs, independent researchers, and patients themselves. The goal wouldn’t be a slightly better version of an existing treatment. It would be to ask whether the thing can be solved at the root.
The gray area we might actually need #
The biggest idea in all of this is probably the creation of a new category of medical innovation: a space where doctors and researchers can work on experimental approaches under serious safeguards, without the constant fear that one unconventional idea could end their career.
That space would need real guardrails. Full transparency, genuine informed consent, independent ethics oversight, careful data collection, public reporting, ongoing safety monitoring, a hard line between experimental and approved treatment, mandatory publication of results, and heavy penalties for deception or recklessness. Inside those boundaries, though, people would have room to explore. The principle is simple to state and hard to build: innovation should be regulated, not forbidden. The aim isn’t to delete the rules. It’s to write rules that keep people safe while still letting progress happen.
Maybe the bottleneck isn’t intelligence #
Healthcare is full of brilliant people, so I don’t think the problem is a shortage of brains or knowledge. I think the system is optimized for something other than radical innovation.
Medicine is optimized for safety. Pharmaceutical companies are optimized for commercial viability. Doctors are optimized for responsibility and risk reduction. Regulators are optimized for preventing harm. Every one of those goals is reasonable on its own. Stacked together, though, they can produce a system that’s exceptional at keeping bad ideas away from patients and, at the same time, painfully slow at letting good new ones through.
IT simply carries a different risk tolerance. A product can fail. A startup can burn through its money. Code can be rewritten, a site can go dark, a project can be shelved. Healthcare doesn’t get that kind of forgiveness, and it shouldn’t. But maybe we can build controlled environments where a little of that flexibility is allowed to exist.
The question is worth asking #
The question isn’t “why are doctors so conservative?” It isn’t “are drug companies evil?” And it definitely isn’t “should we scrap medical regulation.” The better question is this: have we built a healthcare system so afraid of failure that it struggles to discover anything truly revolutionary?
Every breakthrough was once an unconventional idea. Every accepted treatment was once unproven. Every scientific revolution began with someone willing to ask what if we’re wrong about this. Maybe the future of medicine won’t come from polishing the existing system. Maybe it’ll come from building a parallel space where responsible experimentation is encouraged: where doctors can investigate, scientists can push, engineers can build, AI can dig through the data, and patients can take part with their eyes fully open.
Because the greater danger might not be that we experiment too much. It might be that we don’t experiment nearly enough.